Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 18Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Recurrence 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Granulosa cell tumor of the ovary 1Endometrial Neoplasms 1Breast Carcinoma In Situ 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

Tamoxifen 5Specimen Handling 4exemestane 2Letrozole 2Anastrozole 2fezolinetant 1elacestrant 1Testosterone 1Surgical Procedures, Operative 1Omacor 1Neoadjuvant Therapy 1FAPI-46 1Biopsy 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × exemestane × 30 days × Clear all
NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡